Zomedica is an animal health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health. Our mission is to advance the effectiveness and financial well-being of veterinary practitioners by delivering professionally beneficial diagnostic products and services.
We recognize the emotional rewards that come from working in the animal care industry, the sacrifices made in fulfilling the noble veterinary oath, and the challenges impacting veterinarians’ success. Our team is comprised of clinical veterinarians, animal health professionals, innovative scientists, and business experts committed to helping practicing veterinarians remember why they chose to care for animals and recapture the joy in their career.
Zomedica’s goal is to bring gold standard performance to point-of-care testing to improve diagnosis of disease. Improved test performance at the POC provides veterinary healthcare teams with control over their workday and confidence in their ability to diagnose diseases sooner. Improving immunoassay performance—whether through analytical range, accuracy, precision, or other key metrics—at the POC could lead to more accurate and convenient methods for diagnosing complex endocrine and metabolic disorders.
Our diagnostic testing platforms are being developed with these rigorous guidelines in mind. The target specifications for all assays reflect aggressive performance metrics that aim to surpass those of corresponding gold standard technologies. TRUFORMA’s™ assay performance requirements were specifically chosen to meet or exceed reference laboratory performance, thus providing unparalleled service at the POC.
Zomedica engages general-practice veterinarians, veterinary healthcare teams, and veterinary specialists to develop products for clinical use based on clinical needs. Board-certified veterinary internists with disease state expertise guide development of rigorous target specifications for performance of our assays to ensure that our analytical ranges, accuracy, and precision targets will enable first-in-class quantitative measurements for canine and feline populations across a spectrum of medical needs.